did the career thing long enough.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
if partnering talks are 'advanced', ASCO shouldn't have much to do with closing a deal at meetings with BPs.
so who in tustin thought a halt was called for? did they think we'd go back to or close to a 9/21 market cap? did they think the market would say that approval to go to p3 was the same as validating the p2? halting for net 8% is pretty sad
is that now the same as assuming that 1.66 is the result of a bear attack/manipulation/hedge games? or is the market just saying "because of your long series of swinging strikes, see me after unquestionable p3...in the meantime, you're just a day-trading stock"?
Goat...one of the regulars here said he was told that a couple of weeks ago..don't recall whether it was a call or email...call, i think
if the 1st line results are soft, expect that we will be absolutely hammered, mercilessly.
sumpin's been bothering for weeks.
IR supposedly said something like 'don't expect 1st line nsclc to move the needle'.
why, i wonder...
if folks with strong immune systems are in a better situation for bavi (vs. the late stage pancreatic folks who were too immune-weakened to have much benefit, in addition to the advanced cancer they were dealing with), why should we not expect strong 1st line if 2nd line is supposedly so 'exciting'?
who can help me with that?
just posted on Biotech. am i being unreasonable?
honestabe13 Member Profile honestabe13
Monday, May 20, 2013 7:49:14 PM
Re: DewDiligence post# 161394
Post # of 161399
shame on anybody for depending on david sobek's analysis of a biotech with these credentials, from his 'seeking alpha' bio:
'I have a PhD in political science and have been investing for well over a decade. I generally follow small cap biotechnology, MLPs, and mining companies. I hope to provide my thoughts on both topics of interest to investors and particular companies.'
i've followed biotechs for 15 years, and i'm no expert, ...either.
Dew...that's really stretching it, even for you. in fact, it's an absurd reference for this board.
I am long pphm. i respect most of what's on this board, but there is definitely a stench of bias that diminishes all the good stuff here.
people here want pphm pumpers to see the facts and acknowledge them. most of us do both. not many people residing here do not!.
yeah, lots of folks have lost a bundle on Peregrine, lots are up big over time....just like with all biotechs.
apparently, the FDA thought the 11.7 survival might have been a valid number based on contracted, 3rd party results.
if i or my family members or friends were facing this scourge of a disease, i think i'd be taking a look at it when considering options.
you can gloat when it fails P3. till then, it may be wiser to tone it down.
how long till this is deleted?
shame on anybody for depending on david sobek's analysis of a biotech with these credentials, from his 'seeking alpha' bio:
'I have a PhD in political science and have been investing for well over a decade. I generally follow small cap biotechnology, MLPs, and mining companies. I hope to provide my thoughts on both topics of interest to investors and particular companies.'
i've followed biotechs for 15 years, and i'm no expert, ...either.
Dew...that's really stretching it, even for you. in fact, it's an absurd reference for this board.
I am long pphm. i respect most of what's on this board, but there is definitely a stench of bias that diminishes all the good stuff here.
people here want pphm pumpers to see the facts and acknowledge them. most of us do both. not many people residing here do not!.
yeah, lots of folks have lost a bundle on Peregrine, lots are up big over time....just like with all biotechs.
apparently, the FDA thought the 11.7 survival might have been a valid number based on contracted, 3rd party results.
if i or my family members or friends were facing this scourge of a disease, i think i'd be taking a look at it when considering options.
you can gloat when it fails P3. till then, it may be wiser to tone it down.
how long till this is deleted?
pphm may be holding out for a few more pennies, and there may be more that 1 entity trying to grab them while they're not in such a strong position... we shall see if nobody wants them, or if they're stronger than many think..soon.
it is so bizarre watching algos drive the price on hundred share trades
JohnWayne..so which outfits don't use snake oil! there are a hell of a lot of BPs who have been fined for it over many years....why single out pphm?
and how do you know the FDA had very little faith in their P2 data? do you have information not available to the public, or did we miss FDA comments I haven't seen, or are you speculating?
now we'll have to wrestle with the timing of big dilution vs. getting partnered up asap to protect against a short attack after our move up today...
Goat...you've been consistent in that belief for years. sure hope you're in the ballpark :)
luv ya, Goat, but that ain't hapnin'
looks like asco's late posting
tongue in cheek, Goat. the rose-colored glasses here are still amazing after all the disappointments.
some here no doubt thought we were getting Breakthrough designation for a few indications tonite.
not sure why some are so excited about 3 ASCO posters. no presentation, no special highlight press coverage.. how does that make pphm the hot topic?
nobody has answered whether they're new positions or replacements for people who fled a leaking ship.
why do so many assume the former given the company's track record?
i hope that's it, but i'll wait for confirmation from somewhere before i get excited
again...can anyone confirm????
nope...they're talking about big pharma....not us
she's only hit the ground like 'splat' so far as far as i can tell
ayer selling out could be pressuring the pps all by itself
so does anybody here have any info regarding whether the open positions are new/additions vs. replacements?
i would think that would be rather relevant.
somebody on this board knows. please find a way of winking and letting us know.
over a decade of one fiasco after another. the Gold Standard trial turned out to be the Fool's Gold Standard.
If they're going to run this thing up this year, how about starting now?
Well. Brilliant. Yesterday's PR was well-received, wasn't it?
jakedog... the only way the going concern could possibly be gone would be as the result of a partnership with a ton of up-front money. it is not happening like that in the near term. any partnership is only likely to fund continuing trials as of now...
a huge run-up in the share price wouldn't even insure removal of the clause since such gains can be very temporary for stocks like this one.
i expect the going concern to remain until revenue flows from drugs, not from Avid.
sulaco... don't get me wrong...I'm no basher. I've just been here a very long time, and I don't get fooled by their PRs any more.
As expected, it has pulled back from pre-market numbers.
don't be surprised if it finishes around flat.
sulaco...pphm's are generally more generic than this one, which addresses and downplays every single hot program by name in the very short term.
jake...read the safe harbor statement...it's bone-chilling.
it'll be no surprise if the pre-market gain does not hold. there's really nothing new here.
since we're where we were a couple of weeks after the september crash, it's apparent that nobody outside this board apparently believes the trial actually produced noteworthy results.
is this stock nothing but a tool for traders?
How many more times are we supposed to swallow IR's claims that the true value will be known in the coming months?
is $1.40 the true value?
is it the BOD that's no good, or the drug? no proof either of them is worth a crap at the moment.
yeah, biopharm...we'll have our day. we're in talks.
can't get over our $180 million market cap if immunity is where cancer drugs are going...
those abstracts sure went over big this week
shaking the tree? seems like they're cutting it down...
Chris's comment speaks for itself...they know it was intentional, but they do not know why. Best to leave sabotage off the table and focus on whether the FDA will accept the combined arm. If they will, a partner would certainly have less risk justifying a deal.
focus, focus, focus. a deal will move the share price more than arrests.
even though the mouse thing is preclinical, it's potentially very significant since, while they've known the stuff has an effect on the immune system, it's been fuzzy why it has.
if that gets cleared up definitively, the science could have much more value in the lab, at negotiating table, and in the brokerage account....it affects the IP for sure.
Cloak...
with the bid volume being 10 times the ask volume, the share price continues to go down. certainly isn't the way it usually works...
do you consider that to be an indication that somebody is directing this move down intentionally?